Milestone Pharmaceuticals Announces Q2 2025 Financial Results
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) recently shared its financial results for the second quarter ended June 30, 2025. The company has made notable strides to enhance its financial standing as it progresses towards the approval of CARDAMYST™, its lead product.
Positive Regulatory Progress for CARDAMYST™
One of the most significant updates for Milestone is the recent acceptance by the FDA of the company’s response to the Complete Response Letter (CRL) concerning CARDAMYST™ (etripamil) spray. This acceptance has reinstated the hopes for the expected approval of CARDAMYST for managing paroxysmal supraventricular tachycardia (PSVT). With a new Prescription Drug User Fee Act (PDUFA) target date set for December 13, 2025, the team at Milestone is focused and energized.
CEO’s Insights
“With the FDA's acceptance of our CRL response, we are more motivated than ever to meet the needs of patients suffering from PSVT,” remarked Joe Oliveto, President and Chief Executive Officer of Milestone. The recent equity financing, completed with reputable investors, further strengthens their balance sheet, readying them for CARDAMYST's commercial launch, pending FDA approval.
Second Quarter Developments
During the second quarter of 2025, Milestone completed an equity financing round that raised up to $170 million if all warrants are exercised. This funding is set to bolster the company's ability to finalize the development and commercial launch of CARDAMYST™. In addition, Milestone has reached an agreement for a $75 million royalty purchase deal with RTW Investments, extending the payment timeline until the end of 2025.
Financial Overview
By the close of the second quarter, Milestone reported cash and cash equivalents totaling $43.4 million. This was a decrease from $69.7 million recorded at the end of 2024, which reflects the company's ongoing investments into its product pipeline. Notably, there was zero revenue generated in both the quarter in question and in the equivalent quarter from the previous year.
Expenditure Details
Research and development costs saw an increase to $3.7 million, compared to $2.8 million in the same period last year. This rise is mainly attributed to heightened consulting and outside service expenses, although some savings were noted in personnel-related costs. General and administrative expenses decreased to $3.8 million from $5 million year over year, primarily due to reduced legal and professional fees.
Looking Forward with Optimism
As Milestone moves ahead, the focus continues to be on achieving a swift and smooth launch of CARDAMYST™ for PSVT patients should FDA approval be granted. The company is dedicated to managing its operational expenditures wisely while maintaining its enthusiastic outlook for the years to come.
About Etripamil
Etripamil, Milestone's flagship investigational product, is positioned as a cutting-edge treatment enabling rapid patient management of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR). The innovative nasal spray aims to allow patients to self-administer without the necessity for immediate medical supervision, thereby empowering them with better control over their health.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is a dedicated biopharmaceutical firm focused on developing innovative cardiovascular therapies. The commitment to understanding patient needs has positioned Milestone to create solutions that enhance self-management of heart conditions.
Frequently Asked Questions
What are the recent updates on Milestone Pharmaceuticals?
Milestone has announced positive financial results and regulatory progress for CARDAMYST™, with a new PDUFA date set for December 2025.
What is CARDAMYST™?
CARDAMYST™ is Milestone's investigational nasal spray designed to treat episodes of PSVT, offering self-administration for rapid relief.
How much funding did Milestone raise recently?
Milestone raised up to $170 million through a public equity offering, pending warrant exercises, to support development and launch initiatives.
What were the expenses reported by Milestone for Q2 2025?
The company reported R&D expenses of $3.7 million and G&A expenses of $3.8 million for the second quarter of 2025.
What instilled confidence in Milestone's future performance?
The acceptance of Milestone's response to the CRL regarding CARDAMYST™ by the FDA has significantly boosted the team’s confidence for future success.
